TCGA-E7-A519-01A-11R-A26T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 16.68856767
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.350
- ALLOGRAFT_REJECTION+0.310
- INTERFERON_ALPHA_RESPONSE+0.300
- COAGULATION+0.270
- MYOGENESIS+0.270
- APICAL_SURFACE+0.260
- IL6_JAK_STAT3_SIGNALING+0.170
- INFLAMMATORY_RESPONSE+0.140
- PANCREAS_BETA_CELLS+0.130
- KRAS_SIGNALING_UP+0.120
Top 10 suppressed
- G2M_CHECKPOINT-0.600
- PROTEIN_SECRETION-0.600
- E2F_TARGETS-0.590
- UNFOLDED_PROTEIN_RESPONSE-0.550
- MITOTIC_SPINDLE-0.510
- MTORC1_SIGNALING-0.510
- MYC_TARGETS_V1-0.490
- ANDROGEN_RESPONSE-0.450
- MYC_TARGETS_V2-0.450
- UV_RESPONSE_DN-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD006_D.RNA-Seq | EPN | Supratentorial EPN | 0.915 |
| 2 | SRR5088872 | — | — | 0.907 |
| 3 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.890 |
| 4 | SRR1352554 | GTEX | — | 0.886 |
| 5 | MDT-AP-2296 | Med | Medulloblastoma | 0.886 |
| 6 | SJEPD001532_R1.RNA-Seq | EPN | Supratentorial EPN | 0.883 |
| 7 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.880 |
| 8 | SRR1473654 | GTEX | — | 0.879 |
| 9 | TCGA-97-A4M2-01A-12R-A24X-07 | — | cohortA1 | 0.879 |
| 10 | b1f01324-d0ca-4779-9ae0-5348e2613084 | — | — | 0.876 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |